Migraine with aura after clopidogrel withdrawal: evidence of inflammation as a migraine trigger? – Case report

Authors

DOI:

https://doi.org/10.48208/HeadacheMed.2022.36

Keywords:

Patent foramen ovale, Clopidogrel, Migraine with aura, Ischemic Stroke, Inflamation

Abstract

This article presents the case of a PFO (patent foramen ovale) closure patient with double antiplatelet therapy in whom aspirin was discontinued before clopidogrel and that, at clopidogrel withdrawal, presented “de novo” migraine with visual aura attacks. Migraines with aura associated with atrial right-to-left shunts (PFO and other atrial septal defects) are attributed to the arrival of vasoactive substances in the brain, since not cleared by the lungs. In this case, discontinuation of clopidogrel one year after PFO closure induced “de novo” migraine with aura.

Conclusion

Rather than confirming the prophylactic effects of clopidogrel for migraine with aura, its triggering at clopidogrel withdrawal is more likely related to a proinflammatory effect of discontinuing clopidogrel. This proinflammatory effect has been described in cardiological research, and reinforces that patients receiving dual antiplatelet therapy (clopidogrel and aspirin) should always have clopidogrel discontinued before aspirin in order to avoid proinflammatory or pro-thrombotic events.

Downloads

Download data is not yet available.

References

Chow, G., & Ziegelstein, R. C.. Clopidogrel. American Journal of Cardiovascular Drugs, 7(3), 2007:169–171. DOI: https://doi.org/10.2165/00129784-200707030-00003

Hackam DG, Spence JD. Antiplatelet Therapy in ischemic stroke and transient ischemic attack. stroke. 2019;50(3):773-778. DOI: https://doi.org/10.1161/STROKEAHA.118.023954

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes. 2006; 55: 780-784. DOI: https://doi.org/10.2337/diabetes.55.03.06.db05-1394

Savonitto S, D’Urbano M, Caracciolo M, et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of ’bridging’ antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel 2010; 104: 285-291. DOI: https://doi.org/10.1093/bja/aep373

Sathasivam S, Sathasivam S. Patent foramen ovale and migraine: What is the relationship between the two? J Cardiol 2013; 61: 256–259. DOI: https://doi.org/10.1016/j.jjcc.2012.12.005

Zeller JA, Frahm K, Baron R, et al. Platelet-leukocyte interaction and platelet activation in migraine: A link to ischemic stroke? J Neurol Neurosurg Psychiatry 2004; 75: 984–987. DOI: https://doi.org/10.1136/jnnp.2003.019638

Mas JL, Arquizan C, Lamy C, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001; 345: 1740–1746. DOI: https://doi.org/10.1056/NEJMoa011503

Chambers JB, Seed PT, Ridsdale L. Clopidogrel as prophylactic treatment for migraine: a pilot randomised, controlled study. Cephalalgia 2014; 34: 63-68. DOI: https://doi.org/10.1177/0333102414531156

Spencer BT, Qureshi Y, Sommer RJ. A retrospective review of clopidogrel as primary therapy for migraineurs with right to left shunt lesions. Cephalalgia 2014; 34: 933-937. DOI: https://doi.org/10.1177/0333102414523845

Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J. 2006; 27: 647–654. DOI: https://doi.org/10.1093/eurheartj/ehi684

Wilmshurst PT, Nightingale S, Walsh KP et al. Clopidogrel reduces migraine with aura after transcatheter closure of persistent foramen ovale and atrial septal defects. Heart 2005; 91: 1173–1175. DOI: https://doi.org/10.1136/hrt.2004.047746

Schwerzmann M, Wiher S, Nedeltchev K, et al. Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks. J Am Coll Cardiol 2006; 47:446–448.

Downloads

Published

2022-12-28

How to Cite

1.
Folchini CM, Santos PSF, Giraldes J, Machado AB, Kowacs PA. Migraine with aura after clopidogrel withdrawal: evidence of inflammation as a migraine trigger? – Case report. Headache Med [Internet]. 2022 Dec. 28 [cited 2024 Nov. 23];13(4):287-90. Available from: https://headachemedicine.com.br/index.php/hm/article/view/738

Issue

Section

Case Report

Most read articles by the same author(s)

<< < 1 2